Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
Purpose To map functional bone marrow (BM) by 2-deoxy-2-[ 18 F]fluoro- d -glucose ([ 18 F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM. Procedure...
Gespeichert in:
| Veröffentlicht in: | Molecular imaging and biology 2019-04, Vol.21 (2), p.391-398 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 398 |
|---|---|
| container_issue | 2 |
| container_start_page | 391 |
| container_title | Molecular imaging and biology |
| container_volume | 21 |
| creator | Abravan, Azadeh Eide, Hanne Astrid Løndalen, Ayca Muftuler Helland, Åslaug Malinen, Eirik |
| description | Purpose
To map functional bone marrow (BM) by 2-deoxy-2-[
18
F]fluoro-
d
-glucose ([
18
F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM.
Procedures
Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [
18
F]FDG PET before, during, and after treatment. A total of 61 [
18
F]FDG PET scans were analyzed. Vertebral column BM [
18
F]FDG standardized uptake value normalized to the liver (SUV
BMLR
) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [
18
F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney
U
test.
Results
A homogeneous uptake of [
18
F]FDG was observed within the vertebral column prior to treatment. Mean SUV
BMLR
(± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUV
BMLR
was observed from pre- to both mid- and post-therapy (
p
|
| doi_str_mv | 10.1007/s11307-018-1226-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2057135797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2057135797</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-10f88f0e1d73d45e4e4faa42b84889ede96a51143166eac66f662a45a70e079e3</originalsourceid><addsrcrecordid>eNp1kdGK1DAUhoMo7rr6AN5IwBtvqjlJmrSXOsyqMIuyjN6GtD2dzdImNWlZ5i18ZFNmVBC8yuGcL19y-Al5CewtMKbfJQDBdMGgKoBzVehH5BIqxQrOGH-c61KoApTgF-RZSveMgQYunpILXtegAPQl-Xljp8n5A_0QPNIbG2N4oLeYpuATUufpfIf0O8YZm2gHugnDMnraHOnXkNwcg6fb0aXkcrEPYzhEO90d6XUYhvCwam9t50J25P6RWt_RbRzC7Lxr6P7cDT3dLRndWN9ifE6e9HZI-OJ8XpFv19v95lOx-_Lx8-b9rmilqOYCWF9VPUPotOhkiRJlb63kTSWrqsYOa2VLAClAKbStUr1S3MrSaoZM1yiuyJuTd4rhx4JpNnmPFofBegxLMpyVGkSpa53R1_-g92GJPv9upbJXMgmZghPVxpBSxN5M0Y02Hg0ws8ZlTnGZHJdZ4zKr-dXZvDQjdn9u_M4nA_wEpDzyB4x_n_6_9RcCtKDr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2056624041</pqid></control><display><type>article</type><title>Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Abravan, Azadeh ; Eide, Hanne Astrid ; Løndalen, Ayca Muftuler ; Helland, Åslaug ; Malinen, Eirik</creator><creatorcontrib>Abravan, Azadeh ; Eide, Hanne Astrid ; Løndalen, Ayca Muftuler ; Helland, Åslaug ; Malinen, Eirik</creatorcontrib><description>Purpose
To map functional bone marrow (BM) by 2-deoxy-2-[
18
F]fluoro-
d
-glucose ([
18
F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM.
Procedures
Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [
18
F]FDG PET before, during, and after treatment. A total of 61 [
18
F]FDG PET scans were analyzed. Vertebral column BM [
18
F]FDG standardized uptake value normalized to the liver (SUV
BMLR
) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [
18
F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney
U
test.
Results
A homogeneous uptake of [
18
F]FDG was observed within the vertebral column prior to treatment. Mean SUV
BMLR
(± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUV
BMLR
was observed from pre- to both mid- and post-therapy (
p
< 0.05). Mean SUV
BMLR
was significantly higher at post-therapy compared to mid-therapy for patients receiving erlotinib in addition to RT (
p
< 0.05).
Conclusions
RT reduces BM [
18
F]FDG uptake in the vertebral column, especially in the high-dose region. Concomitant erlotinib may stimulate a recovery in BM [
18
F]FDG uptake from mid- to post-therapy.
Trial registration: NCT02714530. Registered 10 September 2015.</description><identifier>ISSN: 1536-1632</identifier><identifier>EISSN: 1860-2002</identifier><identifier>DOI: 10.1007/s11307-018-1226-7</identifier><identifier>PMID: 29916117</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Aged, 80 and over ; Bone cancer ; Bone marrow ; Bone Marrow - diagnostic imaging ; Cancer ; Cancer therapies ; Dose-Response Relationship, Radiation ; Erlotinib Hydrochloride - therapeutic use ; Female ; Fluorine isotopes ; Fluorodeoxyglucose F18 - chemistry ; Glucose ; Humans ; Imaging ; Inhibitor drugs ; Liver ; Liver - diagnostic imaging ; Lung cancer ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Non-small cell lung carcinoma ; Patients ; Positron emission ; Positron emission tomography ; Radiation ; Radiation therapy ; Radiology ; Rank tests ; Research Article ; Spine - diagnostic imaging ; Targeted cancer therapy ; Thorax ; Tomography ; Tomography, X-Ray Computed ; Vertebrae</subject><ispartof>Molecular imaging and biology, 2019-04, Vol.21 (2), p.391-398</ispartof><rights>World Molecular Imaging Society 2018</rights><rights>Molecular Imaging and Biology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-10f88f0e1d73d45e4e4faa42b84889ede96a51143166eac66f662a45a70e079e3</citedby><cites>FETCH-LOGICAL-c438t-10f88f0e1d73d45e4e4faa42b84889ede96a51143166eac66f662a45a70e079e3</cites><orcidid>0000-0003-4839-6705</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11307-018-1226-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11307-018-1226-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27906,27907,41470,42539,51301</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29916117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abravan, Azadeh</creatorcontrib><creatorcontrib>Eide, Hanne Astrid</creatorcontrib><creatorcontrib>Løndalen, Ayca Muftuler</creatorcontrib><creatorcontrib>Helland, Åslaug</creatorcontrib><creatorcontrib>Malinen, Eirik</creatorcontrib><title>Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer</title><title>Molecular imaging and biology</title><addtitle>Mol Imaging Biol</addtitle><addtitle>Mol Imaging Biol</addtitle><description>Purpose
To map functional bone marrow (BM) by 2-deoxy-2-[
18
F]fluoro-
d
-glucose ([
18
F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM.
Procedures
Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [
18
F]FDG PET before, during, and after treatment. A total of 61 [
18
F]FDG PET scans were analyzed. Vertebral column BM [
18
F]FDG standardized uptake value normalized to the liver (SUV
BMLR
) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [
18
F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney
U
test.
Results
A homogeneous uptake of [
18
F]FDG was observed within the vertebral column prior to treatment. Mean SUV
BMLR
(± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUV
BMLR
was observed from pre- to both mid- and post-therapy (
p
< 0.05). Mean SUV
BMLR
was significantly higher at post-therapy compared to mid-therapy for patients receiving erlotinib in addition to RT (
p
< 0.05).
Conclusions
RT reduces BM [
18
F]FDG uptake in the vertebral column, especially in the high-dose region. Concomitant erlotinib may stimulate a recovery in BM [
18
F]FDG uptake from mid- to post-therapy.
Trial registration: NCT02714530. Registered 10 September 2015.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone cancer</subject><subject>Bone marrow</subject><subject>Bone Marrow - diagnostic imaging</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Erlotinib Hydrochloride - therapeutic use</subject><subject>Female</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18 - chemistry</subject><subject>Glucose</subject><subject>Humans</subject><subject>Imaging</subject><subject>Inhibitor drugs</subject><subject>Liver</subject><subject>Liver - diagnostic imaging</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>Rank tests</subject><subject>Research Article</subject><subject>Spine - diagnostic imaging</subject><subject>Targeted cancer therapy</subject><subject>Thorax</subject><subject>Tomography</subject><subject>Tomography, X-Ray Computed</subject><subject>Vertebrae</subject><issn>1536-1632</issn><issn>1860-2002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kdGK1DAUhoMo7rr6AN5IwBtvqjlJmrSXOsyqMIuyjN6GtD2dzdImNWlZ5i18ZFNmVBC8yuGcL19y-Al5CewtMKbfJQDBdMGgKoBzVehH5BIqxQrOGH-c61KoApTgF-RZSveMgQYunpILXtegAPQl-Xljp8n5A_0QPNIbG2N4oLeYpuATUufpfIf0O8YZm2gHugnDMnraHOnXkNwcg6fb0aXkcrEPYzhEO90d6XUYhvCwam9t50J25P6RWt_RbRzC7Lxr6P7cDT3dLRndWN9ifE6e9HZI-OJ8XpFv19v95lOx-_Lx8-b9rmilqOYCWF9VPUPotOhkiRJlb63kTSWrqsYOa2VLAClAKbStUr1S3MrSaoZM1yiuyJuTd4rhx4JpNnmPFofBegxLMpyVGkSpa53R1_-g92GJPv9upbJXMgmZghPVxpBSxN5M0Y02Hg0ws8ZlTnGZHJdZ4zKr-dXZvDQjdn9u_M4nA_wEpDzyB4x_n_6_9RcCtKDr</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Abravan, Azadeh</creator><creator>Eide, Hanne Astrid</creator><creator>Løndalen, Ayca Muftuler</creator><creator>Helland, Åslaug</creator><creator>Malinen, Eirik</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4839-6705</orcidid></search><sort><creationdate>20190401</creationdate><title>Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer</title><author>Abravan, Azadeh ; Eide, Hanne Astrid ; Løndalen, Ayca Muftuler ; Helland, Åslaug ; Malinen, Eirik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-10f88f0e1d73d45e4e4faa42b84889ede96a51143166eac66f662a45a70e079e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone cancer</topic><topic>Bone marrow</topic><topic>Bone Marrow - diagnostic imaging</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Erlotinib Hydrochloride - therapeutic use</topic><topic>Female</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18 - chemistry</topic><topic>Glucose</topic><topic>Humans</topic><topic>Imaging</topic><topic>Inhibitor drugs</topic><topic>Liver</topic><topic>Liver - diagnostic imaging</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>Rank tests</topic><topic>Research Article</topic><topic>Spine - diagnostic imaging</topic><topic>Targeted cancer therapy</topic><topic>Thorax</topic><topic>Tomography</topic><topic>Tomography, X-Ray Computed</topic><topic>Vertebrae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abravan, Azadeh</creatorcontrib><creatorcontrib>Eide, Hanne Astrid</creatorcontrib><creatorcontrib>Løndalen, Ayca Muftuler</creatorcontrib><creatorcontrib>Helland, Åslaug</creatorcontrib><creatorcontrib>Malinen, Eirik</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular imaging and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abravan, Azadeh</au><au>Eide, Hanne Astrid</au><au>Løndalen, Ayca Muftuler</au><au>Helland, Åslaug</au><au>Malinen, Eirik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer</atitle><jtitle>Molecular imaging and biology</jtitle><stitle>Mol Imaging Biol</stitle><addtitle>Mol Imaging Biol</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>21</volume><issue>2</issue><spage>391</spage><epage>398</epage><pages>391-398</pages><issn>1536-1632</issn><eissn>1860-2002</eissn><abstract>Purpose
To map functional bone marrow (BM) by 2-deoxy-2-[
18
F]fluoro-
d
-glucose ([
18
F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM.
Procedures
Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [
18
F]FDG PET before, during, and after treatment. A total of 61 [
18
F]FDG PET scans were analyzed. Vertebral column BM [
18
F]FDG standardized uptake value normalized to the liver (SUV
BMLR
) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [
18
F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney
U
test.
Results
A homogeneous uptake of [
18
F]FDG was observed within the vertebral column prior to treatment. Mean SUV
BMLR
(± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUV
BMLR
was observed from pre- to both mid- and post-therapy (
p
< 0.05). Mean SUV
BMLR
was significantly higher at post-therapy compared to mid-therapy for patients receiving erlotinib in addition to RT (
p
< 0.05).
Conclusions
RT reduces BM [
18
F]FDG uptake in the vertebral column, especially in the high-dose region. Concomitant erlotinib may stimulate a recovery in BM [
18
F]FDG uptake from mid- to post-therapy.
Trial registration: NCT02714530. Registered 10 September 2015.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>29916117</pmid><doi>10.1007/s11307-018-1226-7</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4839-6705</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-1632 |
| ispartof | Molecular imaging and biology, 2019-04, Vol.21 (2), p.391-398 |
| issn | 1536-1632 1860-2002 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2057135797 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Bone cancer Bone marrow Bone Marrow - diagnostic imaging Cancer Cancer therapies Dose-Response Relationship, Radiation Erlotinib Hydrochloride - therapeutic use Female Fluorine isotopes Fluorodeoxyglucose F18 - chemistry Glucose Humans Imaging Inhibitor drugs Liver Liver - diagnostic imaging Lung cancer Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Male Medicine Medicine & Public Health Middle Aged Non-small cell lung carcinoma Patients Positron emission Positron emission tomography Radiation Radiation therapy Radiology Rank tests Research Article Spine - diagnostic imaging Targeted cancer therapy Thorax Tomography Tomography, X-Ray Computed Vertebrae |
| title | Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T09%3A15%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mapping%20Bone%20Marrow%20Response%20in%20the%20Vertebral%20Column%20by%20Positron%20Emission%20Tomography%20Following%20Radiotherapy%20and%20Erlotinib%20Therapy%20of%20Lung%20Cancer&rft.jtitle=Molecular%20imaging%20and%20biology&rft.au=Abravan,%20Azadeh&rft.date=2019-04-01&rft.volume=21&rft.issue=2&rft.spage=391&rft.epage=398&rft.pages=391-398&rft.issn=1536-1632&rft.eissn=1860-2002&rft_id=info:doi/10.1007/s11307-018-1226-7&rft_dat=%3Cproquest_cross%3E2057135797%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2056624041&rft_id=info:pmid/29916117&rfr_iscdi=true |